wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33625227-47CD5FEA-5FEB-4BC0-B651-3647E149EB44
Q33625227-47CD5FEA-5FEB-4BC0-B651-3647E149EB44
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33625227-47CD5FEA-5FEB-4BC0-B651-3647E149EB44
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.
P2860
Q33625227-47CD5FEA-5FEB-4BC0-B651-3647E149EB44
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33625227-47CD5FEA-5FEB-4BC0-B651-3647E149EB44
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c07b2ff69678782654cc95e2a9e1d79c434e3626
P2860
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.